Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Cancer Res. 2012 Dec 12;73(3):1168–1179. doi: 10.1158/0008-5472.CAN-12-2496

Figure 4. Integrin and growth factor signaling in PyMT tumors in vivo.

Figure 4

(A) Lysates from PyMT Trask +/+ and PyMT Trask −/− tumors were analyzed by immunoblotting. Phosphorylation of MAPK (T202/Y204), tyrosine phosphorylation of FAK and their total protein expressions are shown. Each lane corresponds to a tumor derived from a different mouse. (B) The Trask +/+ tumor lysates were used in the R&D Systems p-RTK profiling. This analysis revealed that the predominant active RTK in these tumors is HER2 (labeled A) and to a lesser extent PDGFR (labeled B).